Citations

Clear

90 citation(s) found for "Saunders, Al N".

Sodium-glucose cotransporter-2 inhibitors lower risk of kidney replacement therapy and mortality in bipolar disorder with chronic kidney disease
Singh, Balwinder, Suarez, Maria L. Gonzalez, Baweja, Ritika, Abulseoud, Osama A. , Saunders, Erika F.H., Frye, Mark A., Baweja, Raman , Singh, Balwinder , Singh, Balwinder , Abulseoud, Osama A , Baweja, Ritika , Saunders, Erika F.H. , Frye, Mark A.

Mayo Clinic

Therapeutic Advances in Psychopharmacology | February 20, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/20451253261423437 | PMID 41732711 Get It

Background: Bipolar disorder (BD) is associated with a higher prevalence of chronic kidney disease (CKD) and increased mortality, yet individuals with both BD and CKD are less likely to receive kidney replacement therapy (KRT). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide renal protection in diabetes, but their long-term effects in this high-risk population remain unknown. Objectives: To evaluate whether SGLT2i use reduces the risk of KRT and all-cause mortality in adults with BD and mild-to-moderate CKD (stage ⩽ 3). Design: Observational cohort study with propensity score matching (PSM). Method: In this study using TriNetX (2009–2024) real-world database, 89,369 adults with BD and mild-to-moderate CKD were classified as SGLT2i users ( n = 12,736) or nonusers ( n = 76,633). Primary outcomes were progression to KRT and all-cause mortality over 5 years. Adjusted hazard ratios (aHRs) were estimated using Cox proportional hazards models, and 1:1 PSM reduced confounding. Subgroup analyses examined sex, race/ethnicity, diabetes status, CKD stage, and mood stabilizer use. Results: SGLT2i use was associated with lower risk of KRT (aHR 0.47 (95% CI, 0.42–0.53)) and all-cause mortality (aHR 0.69 (95% CI, 0.65–0.73); both p < 0.001). Protective effects were consistent across subgroups, including individuals receiving lithium, lamotrigine, valproate, or antipsychotics. After PSM (10,967 matched pairs), 5-year KRT-free survival was 94.61% versus 90.99%, and overall survival was 78.67% versus 67.53% (both p < 0.001). Given the observational design, the possibility of residual or unmeasured confounding canot be excluded. Conclusion: SGLT2i therapy in individuals with BD and mild-to-moderate CKD is associated with substantially lower risks of KRT and all-cause mortality. Prospective trials are needed to confirm these findings.
Navigating the Risks Beyond the Label: Unpacking Global Nutritional Supplement Safety
Wardenaar, Floris C. , Burns, Stephen F. , Campos, Marcus Vinícius Simões de , Chan, Yat C. , Claassen-Smithers, Amanda , Dunshea-Mooij, Christel A.E. , Haddou, Salah Eddine, Hoogervorst, Daan , García, P. , Garthe, Ina, Nugent, Anne P. , Aly, Maged Ossama , Schott, Kinta D. , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Campos, Marcus , Chan, Yat , Dunshea-Mooij, Christel , Jagim, Andrew R , Garcia, Pedro Reinaldo , Nugent, Anne P , Aly, Maged Ossama , Saunders, Bryan , Schott, Kinta D , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Stratton, Matthew T , Aussieker, Thorben , Jagim, Andrew R. , Stratton, Matthew T.

Mayo Clinic

International Journal of Sport Nutrition and Exercise Metabolism | December 17, 2025 | Volume: 36 | Issue: 2 | Pages: 134-166

10.1123/ijsnem.2025-0177 | PMID 41468235 Get It

Nutritional supplement use is common among athletes aiming to enhance performance, recovery, and health. However, variable regulatory frameworks and limited safety oversight create risks for inadvertent doping violations. This article provides a global overview of supplement use, relevant authorities, legislation, and safety measures, with a focus on third-party testing (TPT) as a risk-mitigation strategy. Data from six global regions—Africa, Asia, Australia/New Zealand, Europe, Latin America, and North America—were synthesized from peer-reviewed studies, governmental sources, and regional expert contributions. Reported supplement use ranged from 7% to 100% among athletes (variability within regions), with protein powders, vitamins/minerals, creatine, caffeine, and sports drinks being most prevalent. High-risk products (potential anti-doping rule violations), including certain herbal blends, preworkouts, and weight-management supplements, were reported across all regions. While some countries have robust regulatory systems, most lack harmonized or enforceable safety frameworks. TPT programs, which independently verify products for prohibited substances, remain concentrated in the global northwest (Europe, North America, and Australia/New Zealand); awareness and use of TPT certification vary widely, and even in regions with established systems, athlete adherence is inconsistent. Barriers to low-risk supplement use are limited TPT availability, cost, differences in labeling (including language), and cultural factors. Firsthand experiences and perceptions highlight widespread misconceptions about supplement safety and certification. The authors recommend expanded athlete and team-around-the-athlete education, improved global access to TPT low-risk supplements, and policy initiatives to harmonize safety standards. This work emphasizes the need for coordinated international efforts to protect athlete health and integrity while allowing access to evidence-based supplementation.
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer
Song, Long , Aickelin, Uwe , Khorshidi, Hadi Akbarzadeh , Hamy, Anne‐Sophie , Jayasinghe, Yasmin , Lambertini, Matteo , Condorelli, M. , Pistilli, Barbara , Su, H. Irene , Pang, Patrick Cheong‐Iao , Reyal, Fabien , Sukumvanich, Paniti , Minisini, Alessandro Marco , Ruddy, Kathryn J. , Couch, Fergus J. , Stern, Kate, Agresta, Franca, Chin‐Lenn, Laura , Cui, Wanda, Anazodo, Antoinette , Nguyen, Tuong L. , Partridge, Ann, Macheras‐Magias, Mary, Aickelin, Uwe , Akbarzadeh Khorshidi, Hadi , Hamy, Anne-Sophie , Jayasinghe, Yasmin , Lambertini, Matteo , Su, H Irene , Pang, Patrick Cheong-Iao , Ruddy, Kathryn J , Anazodo, Antoinette , Nguyen, Tuong L , Edib, Zobaida , Hickey, Martha , Anderson, Richard A. , Condorelli, Margherita, Demeestere, Isabelle , Ignatiadis, Michail , Chang, Shanton , Nelson, Scott M. , Puglisi, Fabio , Couch, Fergus J. , Olson, Janet E. , Stafford, Lesley , Gorelik, Alexandra , Saunders, Christobel , Sullivan, Elizabeth , Peate, Michelle

Mayo Clinic

Bioengineering | October 28, 2025 | Volume: 12 | Issue: 11 | Pages: 1171

10.3390/bioengineering12111171 | PMID 41301127 Get It

Treatment-induced ovarian function loss is a significant concern for many young patients with breast cancer. Accurately predicting this risk is crucial for counselling young patients and informing their fertility-related decision-making. However, current risk prediction models for treatment-related ovarian function loss have limitations. To provide a broader representation of patient cohorts and improve feature selection, we combined retrospective data from six datasets within the FoRECAsT (Infertility after Cancer Predictor) databank, including 2679 pre-menopausal women diagnosed with breast cancer. This combined dataset presented notable missingness, prompting us to employ cross imputation using the k-nearest neighbours (KNN) machine learning (ML) algorithm. Employing Lasso regression, we developed an ML model to forecast the risk of treatment-related amenorrhea as a surrogate marker of ovarian function loss at 12 months after starting chemotherapy. Our model identified 20 variables significantly associated with risk of developing amenorrhea. Internal validation resulted in an area under the receiver operating characteristic curve (AUC) of 0.820 (95% CI: 0.817–0.823), while external validation with another dataset demonstrated an AUC of 0.743 (95% CI: 0.666–0.818). A cutoff of 0.20 was chosen to achieve higher sensitivity in validation, as false negatives—patients incorrectly classified as likely to regain menses—could miss timely opportunities for fertility preservation if desired. At this threshold, internal validation yielded sensitivity and precision rates of 91.3% and 61.7%, respectively, while external validation showed 92.9% and 60.0%. Leveraging ML methodologies, we not only devised a model for personalised risk prediction of amenorrhea, demonstrating substantial enhancements over existing models but also showcased a robust framework for maximally harnessing available data sources.
Racial and Ethnic Disparities in Outcomes following Preemptive Kidney Transplant Waitlisting in the United States from 2009 to 2024
Adeyemo, Simeon , Crews, Deidra C. , Lentine, Krista L. , Zisman‐Ilani, Yaara , Lincoln, Karen D. , Flores, Glenda M. , Bunnapradist, Suphamai , Ferrey, Antoney , Reddy, Uttam , Muzaale, Abimereki D. , Saunders, Milda R. , Garg, Amit X. , Le, Thu H. , Rhee, Connie M. , Ferrey, Antoney J , Rule, Andrew D , Saunders, Milda , Le, Thu H , Rhee, Connie M , Kalantar-Zadeh, Kamyar , Al Ammary, Fawaz , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | September 16, 2025 | Volume: 37 | Issue: 3 | Pages: 569-581

10.1681/asn.0000000876 | PMID 40956672 Get It

Key Points Among US preemptively waitlisted patients with CKD, deceased donor transplants increased for Black and Hispanic patients, comparable with White patients. Dialysis initiation was higher for waitlisted Asian, Black, and Hispanic patients compared with White patients, mirroring lower living donor transplants. Organ Procurement and Transplantation Network wait time credit and Increasing Organ Transplant Access metric could expand preemptive transplantation. Background Preemptive kidney transplantation (before dialysis initiation) is the optimal therapy for most transplant-eligible advanced patients with CKD. Although prior research has documented racial and ethnic disparities in preemptive referrals, less is known about distinct outcomes after preemptive waitlisting. This study examines the association between race and ethnicity and outcomes for preemptively waitlisted patients. Methods We conducted a secondary analysis of a prospectively maintained US cohort using data from the Scientific Registry of Transplant Recipients. The study population included 98,863 adult first-time kidney transplant candidates who were preemptively waitlisted from January 1, 2009, to December 31, 2020, and followed through December 31, 2024. The exposure of interest was race and ethnicity. The primary outcome was 3-year preemptive deceased donor kidney transplantation, living donor kidney transplantation, or dialysis initiation. We used competing risk models to estimate adjusted subdistribution hazard ratios (aSHRs). Data were stratified into 3-year intervals (2009–2011, 2012–2014, 2015–2017, and 2018–2020). Results Black and Hispanic patients received preemptive deceased donor kidney transplants as often as White patients (era 2018–2020, aSHRs [95% confidence interval (CI)]: 0.99 [95% CI, 0.92 to 1.07] and 1.02 [95% CI, 0.93 to 1.12], respectively), while Asian patients had lower rates (0.78 [95% CI, 0.69 to 0.88]). However, Asian, Black, and Hispanic patients were more likely to initiate dialysis (aSHRs: 1.50 [95% CI, 1.39 to 1.61]; 1.41 [95% CI, 1.34 to 1.49]; and 1.21 [95% CI, 1.14 to 1.29], respectively) and were less likely to receive preemptive living donor kidney transplants than White patients (era 2018–2020, aSHRs: 0.49 [95% CI, 0.44 to 0.54]; 0.31 [95% CI, 0.29 to 0.34]; and 0.61 [95% CI, 0.56 to 0.66], respectively). Conclusions Among waitlisted patients with CKD in the United States between 2009 and 2020, rates of preemptive deceased donor kidney transplantation improved for Black and Hispanic patients and became comparable with White patients. However, Asian, Black, and Hispanic patients experienced higher rates of dialysis initiation and lower rates of preemptive living donor kidney transplantation.
Economic Impact Model of Incorporating Cxbladder Monitor in the Surveillance of Nonmuscle Invasive Bladder Cancer
Tyson, Mark D. , Sfakianos, John P. , Shoskes, Daniel A., Muench, Tobias, Seemann, K. , Saunders, Rhodri , Daneshmand, Siamak

Mayo Clinic

JU Open Plus | April 7, 2025 | Volume: 3 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000271 Get It

Introduction: Guideline recommended surveillance of nonmuscle invasive bladder cancer (NMIBC) involves frequent cystoscopies. Cxbladder Monitor (CxbM) is a noninvasive urinary genomic test with high negative predictive value for NMIBC recurrence. Incorporation of CxbM into surveillance could reduce the frequency, burden, and cost of surveillance. We studied this impact using a theoretical health economic model. Materials and Methods: A Markov model for disease dynamics and decision tree model for surveillance pathways were created for 100 patients with theoretical NMIBC risk stratified by AUA criteria over 5 years from diagnosis. In the standard of care (SOC) arm, cystoscopy was performed per AUA guidelines. In the CxbM surveillance arm, CxbM was used starting 9 months after diagnosis. If positive, cystoscopy was performed per guidelines, but if negative, the cystoscopy was not performed and on the next scheduled encounter. Primary outcome was total budgetary impact. Additional outcomes included number of diagnostic tests, test-related complications, and patients with delayed diagnosis. Results: Compared with SOC, CxbM reduced mean total costs by $68,621 for 100 patients over 5 years or $137.24 per patient per year. Cystoscopy was reduced by 129 (0.31 per patient per year), and there was no difference in delayed cancer diagnosis. Using a probabilistic model, the median cost reduction per patient per year was $160 (95% credible interval −520 to 109) with 86.2% probability of cost savings. Conclusions: In this Markov model, incorporation of CxbM into surveillance for NMIBC reduced cystoscopy without negative impact on cancer detection with cost savings for the majority of simulations run.
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Saunders, David , Hellwig, Lydia D. , Pagani, Austin, Castro, Mauricio De , Poon, Lucas, Ehat, Nate, Heroy, Andrew , Libbus, Joya, Fox, Keiko , Kalra, Sachi, Black, John L. , Scherer, Steven E. , Moyer, Ann M. , Black, John Logan, Haigney, Mark C. , Kalra, Sachi, Arnold, Thomas B. , Turner, Clesson

Mayo Clinic

Pharmacogenomics | February 21, 2025 | Volume: 25 | Issue: 16-18 | Pages: 637-645

10.1080/14622416.2025.2466413 | PMID 39981562 Get It

A Systematic Review and Meta-Analysis of Prophylactic Vasopressors for the Prevention of Peri-Intubation Hypotension
Saunders, Hollie , Khadka, Subekshya, Shrestha, Rabi , Baig, Hassan , Helgeson, Scott A. , Baig, Hassan Z , Helgeson, Scott A , Shrestha, Rabi

Mayo Clinic

Diseases | December 31, 2024 | Volume: 13 | Issue: 1 | Pages: 5

10.3390/diseases13010005 | PMID 39851469 Get It

Background/Objectives: Peri-intubation hypotension is a known complication of endotracheal intubation. In the hospital setting, peri-intubation hypotension has been shown to increase hospital mortality and length of stay. The use of prophylactic vasopressors at the time of sedation induction to prevent peri-intubation hypotension has been raised. This systematic review and meta-analysis aims to review the safety and efficacy of this practice. Methods: The study was fully registered with PROSPERO on 13 October 2022, and screening for eligibility was initiated on 20 September 2024. Randomized controlled trials, along with retrospective or prospective cohort studies, were included in the search. The terms “peri-intubation hypotension”, “vasopressors”, “intubation”, and “anesthesia induced hypotension” were used to search the title/summary in PubMed, Cochrane Library, and Google Scholar databases. An assessment of bias for each study was conducted using the Newcastle-Ottawa Quality Assessment Scale. The primary outcome was the rate of hypotension peri-intubation. Any complications secondary to hypotension or vasopressors were the secondary outcome. Results: We identified 13 studies, which were all randomized controlled studies, to include in the final analysis. The risk ratio for preventing peri-intubation hypotension was 1.6 (95% CI, 1.2–2.14) with the use of prophylactic phenylephrine while giving propofol versus no prophylactic vasopressors and 1.28 (95% CI 1.03–1.60) with the use of ephedrine. Conclusions: These findings suggest that in patients undergoing intubation in the operating room with propofol, prophylactic vasopressors given with induction for intubation decrease the odds of hypotension.
The effect of the COVID-19 pandemic on hospitalization for acute exacerbations of chronic obstructive pulmonary disease
Saunders, Hollie , Thomas, Colleen S. , Balavenkataraman, Arvind , Helgeson, Scott A.

Mayo Clinic

Lung India | December 24, 2024 | Volume: 42 | Issue: 1 | Pages: 69-71

10.4103/lungindia.lungindia_398_24 | PMID 39718925 Get It

Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study
Sykora, Daniel , Olson, Nicole, Kim, B Michelle , Bratcher, Melanie, Elwazir, Mohamed Y. , Young, Kathleen A. , Ryan, Sami, Brodin, Michelle, Anderson, Jan, Saunders, Jeremiah, Ezzeddine, Omar Abou, Bois, John P. , Giudicessi, John R. , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Churchill, Robert , Elwazir, Mohamed , Young, Kathleen , Abou Ezzeddine, Omar, Giudicessi, J R , Cooper, Leslie T , Rosenbaum, Andrew N , AbouEzzeddine, Omar F , Kim, B Michelle , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | November 18, 2024 | Volume: 13 | Issue: 24 | Pages: No page available

10.1161/jaha.124.038965 | PMID 39556701 Get It

Background A multidisciplinary approach improves guideline‐directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist‐led medication therapy management (MTM) program for guideline‐directed medical therapy optimization (MTM versus non‐MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline‐directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event–free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I–II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P =0.83). At follow‐up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P <0.001; NMTM, 29.6 to 58.7; P <0.001) but was higher in MTM ( P =0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P =0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58–90.54]; P =0.002). Conclusions In this retrospective cohort study, a pharmacist‐led MTM program was associated with favorable guideline‐directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF.
Oral Health Care for Children and Youth With Developmental Disabilities: Clinical Report
Sarvas, Elise , Webb, Jessica , Landrigan‐Ossar, Mary, Yin, Larry , HEALTH, SECTION ON ORAL, Beyer, Eric L., Brooks, Chevon, Feldman, Lauren , Kimball, C E, Tate, Anupama Rao , Unkel, John H. , Zaborowski, Matt, Crespin, Matt, Moursi, Amr M. , Beskin, Kera , Agrawal, Rishi , Bell, Deanna S. , Foster, Jessica E.A., Fremion, Ellen , Frierson, Sheryl, Melicosta, Michelle, Saunders, Barbara S. , Srivastava, Siddharth , Vargus‐Adams, Jilda , Kuo, Dennis Z. , Brosco, Jeffrey P. , Sadof, Matthew , Ware, Allysa , Yeargin-Allsopp, Marshalyn, Poon, Jennifer, Yeargin-Allsopp, Marshalyn, Kuznetsov, Alexandra , MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Chatterjee, Debnath , Diaz, Christina D. , Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan-Ossar, Mary, Fehr, James J. , Lin, Yuan‐Chi, Riefe, Jennifer, Sarvas, Elise W , HEALTH, SECTION ON ORAL, Karp, Jeffrey M. , Kimball, C. Eve, Sokal‐Gutierrez, Karen , Noritz, Garey H. , Zuckerman, Katharine E. , Weitzman, Carol Cohen , Yeargin-Allsopp, Marshalyn, Yeargin-Allsopp, Marshalyn, MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Long, Justin, Landrigan-Ossar, Mary, Adler, Adam C.

Mayo Clinic

Pediatrics | July 22, 2024 | Volume: 154 | Issue: 2 | Pages: No page available

10.1542/peds.2024-067603 | PMID 39034828 Get It

Oral health is an essential component of overall health for all individuals. The oral health of children and youth with developmental disabilities (CYDD) involves unique characteristics and needs of which pediatricians and pediatric clinicians can be aware. Risk for oral disease in CYDD is multifactorial and includes underlying medical conditions, medications, and ability to participate in preventive oral health care and treatment, and lack of access to providers is common for this population despite being eligible for Medicaid. Pediatric clinicians are uniquely positioned to support the oral health needs of CYDD and their families through the medical home. This clinical report aims to inform pediatric clinicians about the unique oral health needs of CYDD. It provides guidance on assessing caries risk and periodontal status using structured screening instruments; understanding dental trauma, the role of diet and caries risk, trauma prevention, and malocclusion; and providing anticipatory guidance on oral hygiene that includes tooth brushing, use of fluoridated toothpaste, assessing community water fluoridation, advocating for a dental home by 1 year of age, and transition to adult dental care as part of adolescent health care. It also highlights special considerations for dental treatment rendered under sedation or general anesthesia that CYDD may need. Pediatric clinicians can help reduce risk of CYDD developing dental disease by understanding the unique needs of their patients and their barriers to accessing oral health care in their community, communicating with the child’s dental home, and advocating for safe and accessible dental procedures.